What are the Challenges in Targeting DSBs for Cancer Treatment?
While targeting DSB repair pathways offers promising therapeutic avenues, there are significant challenges. Cancer cells can develop resistance to these treatments by upregulating alternative DNA repair pathways or mutating the drug targets. Furthermore, therapies that induce DSBs can also affect normal cells, leading to side effects such as secondary cancers and tissue damage.
